title: Peironimev-Plus® in the treatment of chronic inflammation of tunica albuginea (Peyronie's disease). results of a controlled study.
abstract: Peyronie's Disease (PD) is a connective tissue disorder involving the growth of fibrous plaques in penile corpora cavernosa (tunica albuginea). The conservative treatment is indicated in the development stage of PD for at least one year after diagnosis and in case of penile pain. This study was conducted to demonstrate the possible effectiveness of the new substances of Peironimev-plus®. Sixty four patients (age: 29-65 years, mean: 52.57 ± 9.06) diagnosed with PD were enrolled in a medical treatment. All patients underwent the following diagnostic tests: penile ultrasound, photographic documentation of penile curvature, IIEF questionnaire (erectile function score), pain evaluation with Visual Analogue pain Scale (VAS). The patients were divided into two treatment groups with different combinations of drugs: A = Peironimev-plus/oral/one tablet-daily + Verapamil injection (peri-lesional) 10 mg/every two weeks + Verapamil iontophoresis/5 mg/three times a week - for 6 months; B = Verapamil injection (peri-lesional) 10 mg/every two weeks + Verapamil iontophoresis/5 mg/three times a week - for 6 months. Intergroup analysis revealed statistically significant differences: in group A the effective plaque size reduction was -30.8% while in the group B the reduction was -18.0% (p=0.000). In group A the improvement of curvature occurred in 85.1% of the cases while in group B this occurred only in 53.5% (p=0.024), moreover the mean curvature decrease was respectively - 8.7° and - 4.6° (p=0.002). IIEF score was significantly improved in group A patients with erectile dysfunction (p=0.02). Our results suggest that Peironimev-plus is an effective drug in treating PD and it may help to prevent the progression of PD.
authors.affiliation: Service of Andrology, Regina Apostolorum Hospital, Via San Francesco, 50 - CAP 00041, Albano Laziale, Rome, Italy. paulisg@libero.it
authors.forename: Gianni
authors.initials: G
authors.lastname: Paulis
authors.forename: Giorgio
authors.initials: G
authors.lastname: Cavallini
authors.forename: Tommaso
authors.initials: T
authors.lastname: Brancato
authors.forename: Rosaria
authors.initials: R
authors.lastname: Alvaro
mesh_terms: D010129:4-Aminobenzoic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000872:Anthocyanins / Q000009:adverse effects / Q000627:therapeutic use*; D000975:Antioxidants / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001691:Biological Therapy / Q000379:methods*; D002908:Chronic Disease; D019587:Dietary Supplements; D004338:Drug Combinations; D007172:Erectile Dysfunction / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000188:drug therapy*; D007529:Isoflavones / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010411:Penile Induration / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D010413:Penis / Q000187:drug effects* / Q000473:pathology; D010936:Plant Extracts / Q000009:adverse effects / Q000627:therapeutic use*; D011429:Propolis / Q000009:adverse effects / Q000627:therapeutic use*; D014700:Verapamil / Q000627:therapeutic use*; D014810:Vitamin E / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*
chemical_list: D000872:Anthocyanins; D000975:Antioxidants; D004338:Drug Combinations; D007529:Isoflavones; D010936:Plant Extracts; C582989:peironimev-plus; D014810:Vitamin E; D011429:Propolis; D014700:Verapamil; D010129:4-Aminobenzoic Acid